Ventures Iv, L.P.5 Am Partn... Net Worth

The estimated Net Worth of Ventures Iv, L.P.5 Am Partn... is at least 25 百万$ dollars as of 16 May 2019. Ventures Partn owns over 615,000 units of Homology Medicines Inc stock worth over 205,935$ and over the last 7 years Ventures sold FIXX stock worth over 24,827,163$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ventures Partn FIXX stock SEC Form 4 insiders trading

Ventures has made over 4 trades of the Homology Medicines Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Ventures sold 615,000 units of FIXX stock worth 13,204,050$ on 16 May 2019.

The largest trade Ventures's ever made was selling 615,000 units of Homology Medicines Inc stock on 16 May 2019 worth over 13,204,050$. On average, Ventures trades about 237,231 units every 36 days since 2018. As of 16 May 2019 Ventures still owns at least 221,435 units of Homology Medicines Inc stock.

You can see the complete history of Ventures Partn stock trades at the bottom of the page.

Insiders trading at Homology Medicines Inc

Over the last 7 years, insiders at Homology Medicines Inc have traded over 108,214,465$ worth of Homology Medicines Inc stock and bought 3,033,333 units worth 51,999,993$ . The most active insiders traders include Steven Gillis、James Edeerfield Management...、Kush Parmar. On average, Homology Medicines Inc executives and independent directors trade stock every 26 days with the average trade being worth of 106,785$. The most recent stock trade was executed by Paul Alloway on 25 March 2024, trading 23,530 units of FIXX stock currently worth 21,883$.

What does Homology Medicines Inc do?

homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.

Complete history of Ventures Partn stock trades at Homology Medicines Inc

Homology Medicines Inc executives and stock owners

Homology Medicines Inc executives and other stock owners filed with the SEC include:

• Arthur Tzianabos,
  President, Chief Executive Officer, Director
• Tim Kelly,
  Chief Technical Operations Officer
• Albert Seymour,
  Chief Scientific Officer
• W. Bradford Smith,
  Chief Financial Officer, Treasurer and Secretary
• Dr. Arthur O. Tzianabos Ph.D.,
  Pres, CEO & Director
• Dr. Albert Seymour Ph.D.,
  Chief Scientific Officer
• W. Bradford Smith CPA, M.B.A.,
  CFO & Treasurer
• Alise Reicin,
  Independent Director
• Kush Parmar,
  Independent Director
• Mary Thistle,
  Independent Director
• Richard Gregory,
  Independent Director
• Matthew Patterson,
  Independent Director
• Steven Gillis,
  Independent Director
• Jeffrey Poulton,
  Director
• Gabriel Cohn,
  Chief Medical Officer
• Cara Mayfield,
  Director of Corp. Communications
• Dr. Deborah Kinch Ph.D.,
  Chief Devel. Officer
• Dr. Julie Jordan M.D.,
  Sr. VP and Head of Clinical Devel. & Operations
• Michael Blum M.B.A.,
  Chief Commercial Officer
• Dr. Gabriel M. Cohn M.B.A., M.D.,
  Chief Medical Officer
• Melissa Gelormini,
  VP of HR
• Theresa McNeely,
  Chief Communications Officer & Patient Advocate
• Dr. Paul Alloway J.D., Ph.D.,
  Chief Legal Officer & Sec.
• Timothy P. Kelly M.B.A.,
  Chief Operating Officer
• Dr. Saswati Chatterjee Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Ventures Iv, L.P.5 Am Co In...,
  
• Ventures Iv, L.P.5 Am Partn...,
  
• Institutes For Bio Medical ...,
  
• Ventures, Llcvv Manager Llc...,
  
• Holdings (Private) Ltd Full...,
  
• Cameron Wheeler,
  Director
• Siyamak Rasty,
  Chief Operating Officer
• James Edeerfield Management...,
  
• James Edeerfield Management...,
  
• Venture Fund Viii, L.P.Arch...,
  
• Springs Capital Management ...,
  
• Venture Fund Viii, L.P.Arch...,
  
• Charles Jr Michaud,
  See Remarks
• Paul Alloway,
  See Remarks
• Michael Lee Blum,
  Chief Commercial Officer
• Julie Jordan,
  Chief Medical Officer